Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential - Toward a consensus

Pharmaceutical Research

Volumn 18, Issue 8, 2001, Pages 1071-1080

  Tucker, G T ^a   Houston, J B ^b   Huang, S M ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; ACETANILIDE; ALBUMIN; ANTIBODY; BUFURALOL; CAFFEINE; CHLORZOXAZONE; CODEINE; COUMARIN; CYTOCHROME; DEBRISOQUINE; DEXTROMETHORPHAN; DICLOFENAC; ENZYME INHIBITOR; ETHOXYRESORUFIN; FELODIPINE; MEPHENYTOIN; METOPROLOL; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PACLITAXEL; PHENACETIN; RECOMBINANT ENZYME; RESORUFIN DERIVATIVE; TESTOSTERONE; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

CONFERENCE PAPER; CRYOPRESERVATION; DRUG DESIGN; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INDUCTION; ENZYME SUBSTRATE; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; PRIORITY JOURNAL;

CARRIER PROTEINS; DRUG DESIGN; DRUG INTERACTIONS; LEGISLATION, DRUG; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RESEARCH;

EID: 0034807892     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010994022294     Document Type: Conference Paper

References (0)